JPWO2020093024A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020093024A5 JPWO2020093024A5 JP2021523009A JP2021523009A JPWO2020093024A5 JP WO2020093024 A5 JPWO2020093024 A5 JP WO2020093024A5 JP 2021523009 A JP2021523009 A JP 2021523009A JP 2021523009 A JP2021523009 A JP 2021523009A JP WO2020093024 A5 JPWO2020093024 A5 JP WO2020093024A5
- Authority
- JP
- Japan
- Prior art keywords
- inventions described
- inventions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754378P | 2018-11-01 | 2018-11-01 | |
| US62/754,378 | 2018-11-01 | ||
| PCT/US2019/059556 WO2020093024A2 (fr) | 2018-11-01 | 2019-11-01 | Procédés d'administration d'anticorps anti-tim -3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022505923A JP2022505923A (ja) | 2022-01-14 |
| JPWO2020093024A5 true JPWO2020093024A5 (fr) | 2022-11-08 |
Family
ID=69159932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523009A Pending JP2022505923A (ja) | 2018-11-01 | 2019-11-01 | 抗ｔｉｍ－３抗体を投与する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220073616A1 (fr) |
| EP (1) | EP3873612A2 (fr) |
| JP (1) | JP2022505923A (fr) |
| CN (1) | CN113301961A (fr) |
| AU (1) | AU2019372436A1 (fr) |
| CA (1) | CA3117371A1 (fr) |
| IL (1) | IL282708A (fr) |
| WO (1) | WO2020093024A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019010392A (es) | 2017-03-02 | 2019-12-02 | Nat Res Council Canada | Moleculas de fusion de ectodominios receptores de tgf-b y sus usos. |
| EP4172208A2 (fr) * | 2020-06-26 | 2023-05-03 | Sorrento Therapeutics, Inc. | Virus oncolytiques exprimant des protéines hybrides immunomodulatrices |
| EP4323003A1 (fr) * | 2021-04-13 | 2024-02-21 | MedImmune, LLC | Anticorps bispécifique ciblant pd-1 et tim-3 |
| WO2022271917A1 (fr) * | 2021-06-24 | 2022-12-29 | Bristol-Myers Squibb Company | Pièges de ligand de facteur de croissance transformant bêta pour le traitement d'une maladie |
| CN116688115B (zh) * | 2022-03-18 | 2024-02-06 | 上海齐鲁制药研究中心有限公司 | 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1252192B1 (fr) | 2000-02-11 | 2006-08-16 | MERCK PATENT GmbH | Amelioration de la demi-vie circulante de proteines de fusion a base d'anticorps |
| DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| PL2032166T3 (pl) * | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| IL300733A (en) | 2010-03-05 | 2023-04-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeting immune modulation |
| WO2013006490A2 (fr) * | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Anticorps se liant spécifiquement à tim3 |
| LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| RU2021114500A (ru) | 2014-02-10 | 2021-06-07 | Мерк Патент Гмбх | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ |
| CN107074948B (zh) * | 2014-07-11 | 2022-01-28 | 根马布股份公司 | 结合axl的抗体 |
| CU20170052A7 (es) * | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2017019897A1 (fr) * | 2015-07-29 | 2017-02-02 | Novartis Ag | Polythérapies comprenant des molécules d'anticorps contre tim -3 |
| WO2017218435A1 (fr) * | 2016-06-13 | 2017-12-21 | Askgene Pharma Inc. | Anticorps monoclonaux spécifiques de pd-l1 pour le traitement et le diagnostic de maladies |
| CN109640988A (zh) * | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| JOP20190013A1 (ar) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| BR112019008861A2 (pt) * | 2016-11-01 | 2019-07-09 | Anaptysbio Inc | anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3) |
| TW201825513A (zh) * | 2016-11-29 | 2018-07-16 | 美商提薩羅有限公司 | 針對ｔ細胞免疫球蛋白及黏蛋白３（ｔｉｍ-３）之抗體 |
| MX2019013023A (es) | 2017-05-12 | 2019-12-18 | Jiangsu Hengrui Medicine Co | Proteina de fusion con receptor tgf-?, y uso farmaceutico de la misma. |
-
2019
- 2019-11-01 EP EP19835890.5A patent/EP3873612A2/fr active Pending
- 2019-11-01 JP JP2021523009A patent/JP2022505923A/ja active Pending
- 2019-11-01 AU AU2019372436A patent/AU2019372436A1/en active Pending
- 2019-11-01 WO PCT/US2019/059556 patent/WO2020093024A2/fr unknown
- 2019-11-01 CA CA3117371A patent/CA3117371A1/fr active Pending
- 2019-11-01 CN CN201980086650.3A patent/CN113301961A/zh active Pending
-
2021
- 2021-04-27 IL IL282708A patent/IL282708A/en unknown
- 2021-04-30 US US17/245,476 patent/US20220073616A1/en active Pending